StemBioSys expands its human chondrocyte offerings

CELLvo™ Human Chondrocytes and CELLvo™ Matrix combine to deliver improved cell attachment and proliferation in vitro while reducing cellular dedifferentiation
SAN ANTONIO, TX – StemBioSys introduced a new culture system designed to help investigators grow human chondrocytes in vitro faster while retaining a natural phenotype. The kit is comprised of CELLvo™ Matrix, a cell-derived extracellular matrix that mimics the chondrocytes’ natural microenvironment, and CELLvo™ Human Articular Chondrocytes, a collection of human chondrocytes sourced from donors of different ages and health statuses. When CELLvo™ Chondrocytes are cultured on CELLvo™ Matrix, chondrocytes attach and proliferate faster, retain a more natural phenotype, and exhibit reduced dedifferentiation. A new web destination providing additional information, experimental data and frequently asked questions is viewable here: https://www.stembiosys.com/chondrocytes.
Chondrocytes are cells that are exclusively found in human articular cartilage; by nature, they proliferate slowly. Published research shows that early passage (P1) CELLvo™ Human Chondrocytes that have been cultured on CELLvo™ Matrix, will home, attach and proliferate more rapidly. In addition, the cultured cells exhibit similar morphology to in vivo chondrocytes and express a high ratio of type 2 collagen (Col2) to type 1 collagen (Col1), which is a clear indication that the chondrocytes are not dedifferentiating in vitro.
Investigators working with CELLvo™ Chondrocytes and CELLvo™ Matrix consistently obtain sufficient quantities of biologically relevant human chondrocytes for cell-based cartilage research. In addition, investigators also have more of an opportunity to study stem cell dedifferentiation and its potential in regenerative medicine.
“As we expand our focus on optimizing chondrocytes for research, we are exploring the addition of sourcing chondrocytes from other age groups, and health statuses, including osteoarthritic profiles,” said Bob Hutchens, President and CEO of StemBioSys. “Our unique chondrocyte culture kit is empowering scientists to achieve truly relevant chondrocyte-related research,” he added.
CELLvo™ Human Chondrocytes are mature, primary cells sourced from young, and otherwise healthy individuals. They may be selected uncultured (P0) or isolated and expanded (P1) on CELLvo™ Matrix. CELLvo™ Matrix is a cell -derived extracellular matrix that is composed of more than 150 proteins that were secreted by stem cells. The final product is deposited on the surface of a culture vessel and cells are gently extracted leaving a native microenvironment on ready-to-use 6-well plates, or 75 cmor 150 cmvented tissue culture flasks. CELLvo™ Matrix provides a unique growth substrate on which cells rapidly and reliably expand in culture.
CELLvo™ Human Chondrocytes are not intended for diagnostic or therapeutic purposes. For more information, visit www.stembiosys.com/chondrocytes or call +1 (210) 877-9323. StemBioSys products are available from leading laboratory supply distributors.
 
About StemBioSys
StemBioSys, Inc., a privately held, San Antonio-based biomedical company, manufactures and develops innovative, advanced cell culture technologies to meet the promise of regenerative medicine in a surging global market. Its patented and proprietary technology platforms – licensed from the University of Texas System – overcome key obstacles to creating clinically useful cell therapies. StemBioSys markets its products to the global research community under the CELLvo™ brand name.
< | >